Answers are grounded in this paper and cite their sources.
When performing a pivotal clinical trial, it may be of interest to assess the probability of success (PoS) of that trial. Initially evaluated when the trial is designed, PoS can be updated as the trial progresses and new information about the drug effect becomes available. Such information can be external to the trial, such as results from trials conducted in parallel, or internal, such as continuing after an interim analysis. We develop a framework to update PoS based on such internal and external information for a time-to-event endpoint and illustrate it using a realistic development program for a new molecule.
No takes yet. Share an insight, caveat, or question.
Rufibach et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: